Search research articles
Contact Us
Filters
Showing results (31-40 of 150) with videos related to
Page
of 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
September 9, 2025
AI-informed retinal biomarkers predict 10-year risk of onset of multiple hematological malignancies
Amritpal Singh, Ajay K Nooka, Gourav Modanwal, et al.
Leukemia & Lymphoma
|
March 15, 2022
Carfilzomib 56 mg/m<sup>2</sup> twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
Katja Weisel, Ajay K Nooka, Evangelos Terpos, et al.
Infection Control and Hospital Epidemiology
|
March 24, 2017
Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study
Nishi N Shah, William McClellan, Christopher R Flowers, et al.
Blood
|
February 3, 2017
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma
Vikas A Gupta, Shannon M Matulis, Jason E Conage-Pough, et al.
Blood Cancer Journal
|
December 18, 2023
Addressing the disparities: the approach to the African American patient with multiple myeloma
Manisha Bhutani, Brandon J Blue, Craig Cole, et al.
Blood Advances
|
January 4, 2018
CD86 regulates myeloma cell survival
Catherine M Gavile, Benjamin G Barwick, Scott Newman, et al.
The American Journal of Gastroenterology
|
February 28, 2007
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study
Yasser H Shaib, Hashem B El-Serag, Ajay K Nooka, et al.
Cancer
|
May 16, 2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients
Ajay K Nooka, Nisha S Joseph, Jonathan L Kaufman, et al.
JAMA Oncology
|
August 22, 2018
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial
Ajay K Nooka, Michael Luhua Wang, Andrew J Yee, et al.
Expert Review of Hematology
|
September 29, 2025
Current experiences with teclistamab in patients with multiple myeloma and renal impairment
Meletios A Dimopoulos, Yael C Cohen, Aurore Perrot, et al.
Page
of 15
Search research articles
Search
Showing results (31-40 of 150) with videos related to
Sort By:
Page
of 15
European Journal of Cancer (Oxford, England : 1990)
|
September 9, 2025
AI-informed retinal biomarkers predict 10-year risk of onset of multiple hematological malignancies
Amritpal Singh, Ajay K Nooka, Gourav Modanwal, et al.
Leukemia & Lymphoma
|
March 15, 2022
Carfilzomib 56 mg/m<sup>2</sup> twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
Katja Weisel, Ajay K Nooka, Evangelos Terpos, et al.
Infection Control and Hospital Epidemiology
|
March 24, 2017
Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study
Nishi N Shah, William McClellan, Christopher R Flowers, et al.
Blood
|
February 3, 2017
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma
Vikas A Gupta, Shannon M Matulis, Jason E Conage-Pough, et al.
Blood Cancer Journal
|
December 18, 2023
Addressing the disparities: the approach to the African American patient with multiple myeloma
Manisha Bhutani, Brandon J Blue, Craig Cole, et al.
Blood Advances
|
January 4, 2018
CD86 regulates myeloma cell survival
Catherine M Gavile, Benjamin G Barwick, Scott Newman, et al.
The American Journal of Gastroenterology
|
February 28, 2007
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study
Yasser H Shaib, Hashem B El-Serag, Ajay K Nooka, et al.
Cancer
|
May 16, 2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients
Ajay K Nooka, Nisha S Joseph, Jonathan L Kaufman, et al.
JAMA Oncology
|
August 22, 2018
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial
Ajay K Nooka, Michael Luhua Wang, Andrew J Yee, et al.
Expert Review of Hematology
|
September 29, 2025
Current experiences with teclistamab in patients with multiple myeloma and renal impairment
Meletios A Dimopoulos, Yael C Cohen, Aurore Perrot, et al.
Page
of 15